Logo image of M3V.DE

MEVIS MEDICAL SOLUTIONS AG (M3V.DE) Stock Analyst Earnings Estimates

FRA:M3V - Deutsche Boerse Ag - DE000A0LBFE4 - Common Stock - Currency: EUR

25.8  +0.4 (+1.57%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022
Revenue
YoY % growth
M3V.DE revenue by date.M3V.DE revenue by date.
17.131M
-5.21%
16.214M
-5.35%
18.762M
15.71%
EBITDA
YoY % growth
M3V.DE ebitda by date.M3V.DE ebitda by date.
6.038M
-18.38%
4.545M
-24.74%
6.563M
44.41%
EBIT
YoY % growth
M3V.DE ebit by date.M3V.DE ebit by date.
5.871M
-17.80%
4.419M
-24.73%
6.47M
46.41%
Operating Margin
M3V.DE operating margin by date.M3V.DE operating margin by date.
34.27%27.25%34.48%
EPS
YoY % growth
M3V.DE eps by date.M3V.DE eps by date.
N/AN/AN/A

All data in EUR

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in EUR

Recent Earnings VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
M3V.DE Yearly EPS VS EstimatesM3V.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 1 2 3
Recent Revenue VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q4 2022
Q2Q % growth
10.216M
25.59%
%
Q2 2022
Q2Q % growth
8.546M
5.76%
%
Q4 2021
Q2Q % growth
8.134M
-3.79%
%
Q2 2021
Q2Q % growth
8.08M
-6.88%
%
Q4 2020
Q2Q % growth
8.454M
-8.69%
%
Q2 2020
Q2Q % growth
8.677M
-1.56%
%
M3V.DE Yearly Revenue VS EstimatesM3V.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A